Corporate, Emerging Companies + Venture Capital, and Life Sciences
This program has been cancelled.
It is likely that the equity and debt markets will remain closed throughout 2009 and into the foreseeable future to all but the largest pharmaceutical, biotechnology, and medical device companies. How can the rest of the market access the capital needed to make the most of the growth opportunities?Royalty monetization and revenue interest financing offer innovative companies attractive and available alternatives to their financing challenges. These financing vehicles can be tailored to meet a company's individual, near-term financial needs without the dilution associated with equity financing, the restrictive covenants of commercial debt, or the sacrifice of long-term value associated with product development partnerships.
Join your colleagues, Paul Capital Healthcare, and Morrison & Foerster LLP for an interactive discussion of how to put royalty monetization and revenue interest financing to work in achieving your corporate growth objectives.
Speakers:Warren D. Cooper, President and Chief Executive Officer, Prism Pharmaceuticals, Inc.John Leone, Partner, Paul Capital HealthcareKristian Wiggert, Morrison & Foerster LLP
This seminar will also be presented in Palo Alto.
©1996-2019 Morrison & Foerster LLP. All rights reserved.